No photo of Mark Agulnik

View Scopus Profile

Mark Agulnik

  • 2281 Citations
20012023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Certifications and Licenses

Hematology
Medical Oncology

Training Experience

2001Residency, Dalhousie University, Canada
2004Fellowship, Univ. of Illinois Hospital

Education/Academic qualification

MD, McGill University

… → 1998

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 13 Similar Profiles
Sarcoma Medicine & Life Sciences
Head and Neck Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Gastrointestinal Stromal Tumors Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2005 2023

Prot #BLU-285-1303: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Agulnik, M.

Syneos Health, Inc., Blueprint Medicines Corporation

9/20/18 → 9/20/21

Project: Research project

NADC Pilot

Agulnik, M., Roh, M. & Song, C.

National Cancer Institute

8/10/18 → 7/31/23

Project: Research project

Neoplasms
Medicine
N-acetoacetyl-N-deacetylcolchicine
Research
Population

The Robert H. Lurie Comprehensive Cancer Center

Agulnik, M., Awatramani, R., Backman, V., Benson III, A. B., Carthew, R. W., Cella, D., Chakravarti, D., Chandel, N., Crispino, J. D., Cristofanilli, M., Eklund, E. A., Frankfurt, O., Gordon, L. I., Green, K. J., Hahn, E. A., Horbinski, C. M., Horvath, C. M., Hussain, M., James, C. D., Kelleher, N. L., Khan, S. A., LaBonne, C., Larson, A. C., Matei, D. E., Meade, T. J., Mondragon, A., Mrksich, M., Munshi, H. G., Murphy, A. B., Penedo, F. J., Perlman, H. R., Peter, M. E., Platanias, L. C., Rademaker, A. W., Rappoport, J. Z., Rosenzweig, A. C., Scheidt, K. A., Simon, M. A., Sosman, J. A., Spring, B., Wei, J., Weiss, E. L. & Woloschak, G. E.

National Cancer Institute

8/10/18 → 7/31/23

Project: Research project

Neoplasms
Medicine
Research
Population

Prot #KCP-330-020: A Phase 2-3, Multicenter, Randomized, Double-Blind Study of Selinexor (KPT-330) Versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Agulnik, M.

Clintrax Global, Inc., Karyopharm Therapeutics Inc.

2/27/18 → 2/27/21

Project: Research project

Prot #20130232: A Phase 1b/3 Multicenter, Randomized, Open-label Trial of Talimogene Laherparepvec in combination with Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Agulnik, M.

Amgen, Inc.

6/23/16 → 6/23/19

Project: Research project

Research Output 2001 2018

  • 2281 Citations
  • 49 Article
  • 24 Review article
  • 3 Comment/debate
  • 1 Short survey
11 Citations

Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)

Ma, B. B. Y., Lim, W. T., Goh, B. C., Hui, E. P., Lo, K. W., Pettinger, A., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y. C., Chopra, A., Kish, J. A., Chung, C. H., Adkins, D. R., Cullen, K. J., Gitlitz, B. J., Lim, D. W., To, K. F., Chan, K. C. A., Lo, Y. M. D. & 5 othersKing, A. D., Erlichman, C., Yin, J., Costello, B. A. & Chan, A. T. C., Jan 1 2018, In : Journal of Clinical Oncology. 36, 14, p. 1412-1418 7 p.

Research output: Contribution to journal › Article

Multicenter Studies
Survival Rate
Ligands
Disease-Free Survival
Biomarkers
4 Citations

Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment

Rosenberg, A. & Agulnik, M., Apr 1 2018, In : Current Treatment Options in Oncology. 19, 4, 19.

Research output: Contribution to journal › Comment/debate

Epithelioid Hemangioendothelioma
Sarcoma
Immunotherapy
Clinical Trials
Therapeutics

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma

Agulnik, M. & Attia, S., Jun 21 2018, (Accepted/In press) In : Targeted Oncology. p. 1-6 6 p.

Research output: Contribution to journal › Article

Sarcoma
Gastrointestinal Stromal Tumors
Leiomyosarcoma
Therapeutics
Synovial Sarcoma

Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: A case report and review

Chae, Y. K., Chiec, L., Adney, S. K., Waitzman, J., Costa, R., Carneiro, B., Matsangou, M., Agulnik, M., Kopp, P. A. & Giles, F., Jun 15 2018, In : Oncotarget. 9, 46, p. 28281-28289 9 p.

Research output: Contribution to journal › Article

Posterior Leukoencephalopathy Syndrome
Takotsubo Cardiomyopathy
Thyroid Neoplasms
Protein-Tyrosine Kinases
Pharmaceutical Preparations
2 Citations

A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas

Agulnik, M., Costa, R. L. B., Milhem, M., Rademaker, A. W., Prunder, B. C., Daniels, D., Rhodes, B. T., Humphreys, C., Abbinanti, S., Nye, L., Cehic, R., Polish, A., Vintilescu, C., McFarland, T., Skubitz, K., Robinson, S., Okuno, S. & Van Tine, B. A., Jan 1 2017, In : Annals of Oncology. 28, 1, p. 121-127 7 p.

Research output: Contribution to journal › Article

Sarcoma
Disease-Free Survival
Survival Rate
Vascular Endothelial Growth Factors
Confidence Intervals